F Fuzkk Atlas of India
#77FUZKK atlas leaders 1–100

Novartis India Ltd

Maharashtra · Maharashtra / Mumbai–Pune

Baseline manufacturing scope

Manufacturing profile

Baseline manufacturing scope

State / territory: Maharashtra

Pharmaceutical cluster: Maharashtra / Mumbai–Pune

Selection basis

The company is placed in positions 1–100 as a major Indian manufacturer, exporter, API/CDMO, generics, vaccine or biopharma participant.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Licence status, GMP status and the actual site portfolio must be rechecked through CDSCO and the relevant State Drug Controller.

Representative manufacturing and QC chain

  1. 1Confirmation of the actual product portfolio
  2. 2Inventory of equipment, methods and export formats
  3. 3Supplier and incoming controls
  4. 4Calibration, process validation and change control
  5. 5Data integrity, batch evidence and release readiness

Relevant FUZKK packages

India: national essential medicines QC packageChina: national essential medicines QC packageLumex QC SuiteLabEx QC SuiteMedical Device QMS Suite

Product/API utilities

Assay & Impurities Result Reviewer

Lumex — instrumental QC

Genotoxic Impurity Screener M7Content Uniformity Acceptance ValueSystem Suitability Parameters Checker

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerResidual Solvents GC Quality CheckerWater Content KF Quality Checker

Medical Devices — equipment and software lifecycle

Release Readiness CheckerSupplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerData Integrity Security CheckerRequirement Traceability Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Licence status, GMP status and the actual site portfolio must be rechecked through CDSCO and the relevant State Drug Controller.

Methodology